Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Udonitrectag - MimeTech

Next Previous
Drug Profile

Udonitrectag - MimeTech

Alternative Names: MT-8; Negermin lysine salt; REC 0/0559; REC-0559

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Universita degli Studi di Firenze
  • Developer MimeTech; Recordati
  • Class Anti-inflammatories; Antianaemics; Antiglaucomas; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Keratitis
  • Phase I/II Diabetic foot ulcer
  • Preclinical Choroideraemia; Dry eyes; Glaucoma; Lung transplant rejection; Myocardial infarction; Pressure ulcer; Reperfusion injury; Retinitis pigmentosa; Skin disorders; Varicose ulcer
  • No development reported Sickle cell anaemia

Most Recent Events

  • 19 Jul 2023 Preclinical trials in Varicose ulcer in Italy (unspecified route) (MimeTech pipeline, July 2023)
  • 28 Mar 2023 Udonitrectag is still in preclinical development for Glaucoma in Italy (MimeTech pipeline, March 2023)
  • 28 Mar 2023 Udonitrectag is still in preclinical development for Dry-eyes in Italy (MimeTech pipeline, March 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top